CLGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.08M

+1177.23%

-0.070

-79.41%

1.10M

-46.7%

-0.190

+46.15%

9.82M

+5414.99%

0.350

-225%

Estimates Revision

The market is revising Downward the revenue expectations for CollPlant Biotechnologies Ltd. (CLGN) for FY2025, with the revenue forecasts being adjusted by -50.8% over the past three months. During the same period, the stock price has changed by -37.18%.

Revenue Estimates for FY2025

Revise Downward

-50.8%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+138.1%

In Past 3 Month

Stock Price

Go Down

-37.18%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

11.00

Averages

11.00

High

11.00

Current: 0.000

Low

11.00

Averages

11.00

High

11.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$14

2025-03-27

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-03-27

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$14

2025-02-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-02-12

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$14

2025-02-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-02-04

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN.O) is -13.45, compared to its 5-year average forward P/E of 9.25. For a more detailed relative valuation and DCF analysis to assess Collplant Biotechnologies Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

9.25

Current PE

-13.45

Overvalued PE

43.72

Undervalued PE

-25.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

55.73

Current PS

1.25

Overvalued PS

168.98

Undervalued PS

-57.51

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLGN News & Events

Events Timeline

No data

News

4.0

2025-11-29NASDAQ.COM

D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)

4.0

2025-11-28Benzinga

D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact

7.5

2025-11-26Newsfilter

CollPlant Partners with U.S. Logistics Center to Expand North American Market

People Also Watch

Frequently Asked Questions

What is Collplant Biotechnologies Ltd (CLGN) stock price today?

The current price of CLGN is 1.47 USD — it has increased 2.08 % in the last trading day.

What is Collplant Biotechnologies Ltd (CLGN)'s business?

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

What is the price predicton of CLGN Stock?

What is Collplant Biotechnologies Ltd (CLGN)'s revenue for the last quarter?

Collplant Biotechnologies Ltd revenue for the last quarter amounts to 77.00K USD, increased 1825.00 % YoY.

What is Collplant Biotechnologies Ltd (CLGN)'s earnings per share (EPS) for the last quarter?

Collplant Biotechnologies Ltd. EPS for the last quarter amounts to -0.27 USD, decreased -28.95 % YoY.

What changes have occurred in the market's expectations for Collplant Biotechnologies Ltd (CLGN)'s fundamentals?

How many employees does Collplant Biotechnologies Ltd (CLGN). have?

Collplant Biotechnologies Ltd (CLGN) has 57 emplpoyees as of January 10 2026.

What is Collplant Biotechnologies Ltd (CLGN) market cap?

Today CLGN has the market capitalization of 18.78M USD.